# Pharmacokinetic Modeling of Fentanyl Citrate and Norfentanyl in **Calves Using a Nonlinear Mixed-Effects Approach**

## Joe Smith<sup>2,3\*</sup>, <u>Claude Magnard<sup>1\*</sup></u>, Yeon-Jung Seo <sup>2,4</sup>, Pauline Traynard<sup>1</sup>, Jonathan P. Mochel<sup>2</sup>

(1) Simulations Plus, Lixoft division, Antony, France, (2) Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, (3) Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN, (4) Department of Statistics, University of Pittsburgh, PA (\*) co-lead authors.

**SHSimulationsPlus** Cognigen DILIsym Services Lixoft

**CONTACT INFORMATION:** claude.magnard@simulations-plus.com

### **GOAL**

Fentanyl citrate is a potent opioid agonist commonly used as an analgesic in animal studies, providing several hours of pain relief during surgical and other medical procedures [1].



Characterize the kinetics of fentanyl citrate and norfentanyl using a nonlinear mixed-effects (NLME) modeling approach



Use this model to compare competing dosing regimens that achieve therapeutic steady-state concentrations of fentanyl and norfentanyl, while minimizing systemic toxicity in calves.

#### WORKFLOW 16 calves Data Single iv dose, either 2.5 µg/kg or 5.0 µg/kg Parent (fentanyl) and metabolite (norfentanyl) measured for 24h after dosing Joint model capturing parent and metabolite data Population modeling and inter-individual variability in Monolix Selection of best structural and statistical model Predict the response to continuous infusion and Compare dosing intermittent boluses, with and without loading dose

**IMPORT** your estimated model in one click




Post-process simulations to find the best regimen combining safety and efficacy

### **PARENT-METABOLITE MODEL ESTIMATED IN MONOLIX**

# Model selection in Sycomore

Project name All None	🚸 Rating 🕸 🛛	lCc (IS)≁	Structural model	Observation model	Individual model 🤳
r02_parent_3cpt	***	2157.77	lib: bolus_3cpt_ClV1 Q2V2Q3V3.txt	<b>yFentanyl:</b> comb1	CI V1 Q2 V2 Q3 V3
r03_parent_met	***	3232.47	bolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	yFentanyl: comb1 yNorfentanyl: comb1	V1 CL Q2 V2 Q3 V3 Clr Kpm
r04_bis_wo_sim_annealin	g ***	3223.31	bolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	yFentanyl: prop yNorfentanyl: const	V1 CL Q2 V2 Q3 V3 Cln Kpm
r04_parent_met_errormod	lel ★★★	3222.22	bolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	yFentanyl: prop yNorfentanyl: const	V1 CL Q2 V2 Q3 V3 Cln Kpm
r05_parent_met_noREV2Clr	nCl ★★★	3214.48	bolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	<b>yFentanyl:</b> prop <b>yNorfentanyl:</b> const	V1 Cl Q2 V2 Q3 V3 Cln Kpm
r06_parent_met_corrQ3Kp	m <b>**</b> *	3208.38	bolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	yFentanyl: prop yNorfentanyl: const	V1 Cl Q2 V2 Q3 V3 Cln Kpm
r07_parent_met_corrV1Q3K	pm ★ ★ 🛣	3209.04	Dolus_noFPE_3cptP 1cptM_uni_V1ClQ2V 2Q3V3ClmKpm.txt	yFentanyl: prop yNorfentanyl: const	V1 Cl Q2 V2 Q3 V3 Clm Kpm
_parent Oro2_	tment: BIC lower	parent_met_err		or04_bis_wo_sim_annealing	-O r06_parent_met_corrQ3Kpm
			r05_parent_me	et_noREV2CImCI	• r07 parent met corrV1Q3Kp


# Structural model



# Statistical model

PARAMETERS	DISTRIBUTIONS	RANDOM EFFECTS	- CORRELATION +
		Select: All   None	#1
V1			
Cl			
Q2			
V2			
Q3			
V3		<ul><li>✓</li></ul>	
Clm			
Kpm		~	<b>~</b>

# Population Parameters Visual Predictive Checks




#### Save time and focus on the results with built-in DIAGNOSTIC **PLOTS**

Keep track of your MODEL BUILDING steps and compare runs with Sycomore

**Quickly define** populations and simulate them **EFFICIENTLY** in **C++** 

## **COMPARE DOSING REGIMEN IN SIMULX**

How many ids stay in target after constant IV infusion (CI) vs. individual boluses (IB) of fentanyl, with or without 1. loading dose?






For each replicate study:

- For each id in each group, compute outcomes: Cmax, AUC\_12h
- For each group, compute endpoints:
  - % of ids with Cmax below safety target -
  - % of ids with AUC above efficacy target
  - % of ids with both Cmax and AUC in target


### Distribution of endpoint (%ids in target) over replicates for:



**Post-process** your simulations with built-in **OUTCOMES & ENDPOINTS** 

1,200 1.400


time




Cl of 1.2mg improves safety of fentanyl compared to IB. The efficacy of fentanyl seems improved with a loading dose.

2. In a scenario where fentanyl is given with a CI, does a loading dose improve therapeutic efficacy (characterized in terms of mean AUC at 12h)? What is the probability of technical success to reach higher systemic exposure of fentanyl with a loading dose?


Distribution of mean(AUC) over replicates for infusion with/without loading dose



T-test to check if mean(AUC) is higher with a loading dose for each replicate study



Estimated success rate of reaching higher systemic exposure of fentanyl with a loading dose = 75%.



**STATISTICAL TESTS to check** trial success in a few clicks



These simulations assume that only the parent drug Fentanyl has an effect. The same investigation could be done for the metabolite or a combination of parent and metabolite. CI: total amount 1.2mg over 12h IB: 0.1 mg QH. Safety target: Cmax < 1ug/L. Efficacy target: AUC\_12h > 0.3ug/L\*12h. Loading dose: 50ug.